Does vimentin help to delineate the so-called 'basal type breast cancer'?
BACKGROUND
Vimentin is one of the cytoplasmic intermediate filament proteins which are the major component of the cytoskeleton. In our study we checked the usefulness of vimentin expression in identifying cases of breast cancer with poorer prognosis, by adding vimentin to the immunopanel consisting of basal type cytokeratins, estrogen, progesterone, and HER2 receptors.


METHODS
179 tissue specimens of invasive operable ductal breast cancer were assessed by the use of immunohistochemistry. The median follow-up period for censored cases was 90 months.


RESULTS
38 cases (21.2%) were identified as being vimentin-positive. Vimentin-positive tumours affected younger women (p = 0.024), usually lacked estrogen and progesterone receptor (p < 0.001), more often expressed basal cytokeratins (<0.001), and were high-grade cancers (p < 0.001). Survival analysis showed that vimentin did not help to delineate basal type phenotype in a triple negative (ER, PgR, HER2-negative) group. For patients with 'vimentin or CK5/6, 14, 17-positive' tumours, 5-year estimated survival rate was 78.6%, whereas for patients with 'vimentin, or CK5/6, 14, 17-negative' tumours it was 58.3% (log-rank p = 0.227).


CONCLUSIONS
We were not able to better delineate an immunohistochemical definition of basal type of breast cancer by adding vimentin to the immunopanel consisted of ER, PgR, HER2, CK5/6, 14 and 17 markers, when overall survival was a primary end-point.
Kusinska
Renata U
RU
Department of Pathology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland. renata.kusinska@gmail.com
Kordek
Radzislaw
R
Pluciennik
Elzbieta
E
Bednarek
Andrzej K
AK
Piekarski
Janusz H
JH
Potemski
Piotr
P
D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D014746:Vimentin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D014746:Vimentin
Mod Pathol. 2008 Oct;21(10):1183-91
18536655
Pol J Pathol. 2005;56(3):107-10
16334976
Breast Cancer Res. 2007;9(6):404; author reply 405
18279542
Cancer Res. 2003 May 15;63(10):2658-64
12750294
Oncology. 2005;69(6):478-85
16410686
J Pathol. 2005 Aug;206(4):451-7
15906273
J Pathol. 1989 Apr;157(4):299-306
2469782
Mod Pathol. 2005 Oct;18(10):1321-8
15990899
Pathology. 2002 Jun;34(3):230-2
12109782
Am J Pathol. 1990 Nov;137(5):1143-55
1700618
Am J Pathol. 1990 Nov;137(5):1059-64
2173410
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Int J Cancer. 1996 Jul 29;67(3):353-6
8707408
Cancer Res. 1989 Aug 1;49(15):4258-63
2472876
Clin Cancer Res. 2009 Apr 1;15(7):2302-10
19318481
Breast Cancer Res. 2007;9(1):R16
17263897
Cancer Res. 2001 Jul 1;61(13):5168-78
11431356
Tumori. 2009 Jan-Feb;95(1):53-62
19366057
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
12917485
Breast Cancer Res. 2007;9(5):R65
17910759
Am J Pathol. 1990 Jan;136(1):219-27
2153347
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
Nature. 2000 Aug 17;406(6797):747-52
10963602
Am J Pathol. 1997 Feb;150(2):483-95
9033265
Cells Tissues Organs. 2007;185(1-3):191-203
17587825
J Pathol. 2004 Jun;203(2):661-71
15141381
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
15328174
J Clin Pathol. 1993 May;46(5):441-5
7686566
Am J Pathol. 2002 Dec;161(6):1991-6
12466114
BMC Cancer. 2007 Jul 24;7:134
17650314
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
3893381
Int J Oncol. 2004 Aug;25(2):249-58
15254720
Clin Cancer Res. 2008 Mar 1;14(5):1368-76
18316557
J Pathol. 1996 Oct;180(2):175-80
8976877
Am J Clin Pathol. 1987 Sep;88(3):286-96
2443000